Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma.
- Author:
Xiao-jian GU
1
;
Jian-lin LU
;
Ren-sheng LAI
;
Ya-da ZHANG
;
Ping ZHANG
;
Zi-jie LU
;
Qing-yi ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Diagnosis, Differential; Humans; Immunohistochemistry; Keratins; biosynthesis; Male; Prostate-Specific Antigen; biosynthesis; Prostatic Neoplasms; diagnosis; metabolism; pathology; Staining and Labeling; Tumor Suppressor Protein p53; biosynthesis
- From:National Journal of Andrology 2006;12(4):340-342
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo improve the level of clinical diagnosis and differential diagnosis of benign and malignant prostate lesions.
METHODSOne hundred and nine cases of prostate cancer and prostate hyperplasia were evaluated by the expression of high molecular weight cytokeratin (CK34BE12), prostate specific antigen (PSA) and protein P53 gene using the immunohistochemical technique.
RESULTSThe basal-cells in all of the benign lesions were stained with the CK34BE12 and PSA, while it had not immunoreactivity with P53. In contrast, the prostate carcinoma were not stained or partly stained with the CK34BE12 and PSA, but P53 show significant immunoreactivity with the tissue.
CONCLUSIONBased on the routine histological studies with the expression of CK34BE12 and PSA together, they can indicate the existence of basal-cell distinctly and show indirectly whether the basal-cell is integrated. Combining the expression of P53 to determine the existence of cancer gene, it can help to distinguish benign and malignant prostate lesions.
